$GLUE
Monte Rosa Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004927 Filed on March 29, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.387M $5.257M $15.73M
YoY Change 186.28% 153.59% 292.68%
% of Gross Profit
Research & Development $17.92M $18.13M $57.16M
YoY Change 93.2% 83.87% 138.1%
% of Gross Profit
Depreciation & Amortization $800.0K $809.0K $2.100M
YoY Change 166.67% 262.78% 320.0%
% of Gross Profit
Operating Expenses $24.30M $23.39M $72.88M
YoY Change 111.25% 95.94% 160.2%
Operating Profit -$24.30M -$72.88M
YoY Change 111.25% 160.2%
Interest Expense $149.0K -$53.00K $46.00K
YoY Change 2383.33% 32.5% 411.11%
% of Operating Profit
Other Income/Expense, Net $370.0K $0.00 -$1.076M
YoY Change -147.93% -100.0% -86.33%
Pretax Income -$23.93M -$23.44M -$9.884M
YoY Change 94.95% 19.25% -2.21%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.93M -$23.44M -$73.96M
YoY Change 94.95% 19.25% 106.13%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$513.6K -$937.6K -$2.958M
COMMON SHARES
Basic Shares Outstanding 46.63M 46.51M 25.00M
Diluted Shares Outstanding 46.60M 25.00M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $317.2M $346.1M $346.1M
YoY Change 88.3% 729.93%
Cash & Equivalents $138.3M $346.1M $346.1M
Short-Term Investments $178.9M $0.00
Other Short-Term Assets $3.203M $2.595M $2.595M
YoY Change -2.08% 37.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $320.4M $348.7M $348.7M
YoY Change 86.58% 699.86% 699.86%
LONG-TERM ASSETS
Property, Plant & Equipment $13.40M $12.33M $12.33M
YoY Change 73.25% 166.6% 166.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.333M $0.00 $5.338M
YoY Change 358.16% 358.59%
Total Long-Term Assets $25.64M $17.66M $17.66M
YoY Change 188.21% 205.22% 205.22%
TOTAL ASSETS
Total Short-Term Assets $320.4M $348.7M $348.7M
Total Long-Term Assets $25.64M $17.66M $17.66M
Total Assets $346.0M $366.3M $366.3M
YoY Change 91.58% 641.89% 641.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.511M $6.558M $6.558M
YoY Change -38.42% -7.19% -7.19%
Accrued Expenses $7.979M $10.08M $10.08M
YoY Change 352.07% 298.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.49M $16.64M $16.64M
YoY Change 37.39% -43.17% -43.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.640M $2.176M $2.176M
YoY Change 699.16% 103.94%
Total Long-Term Liabilities $7.640M $2.176M $2.176M
YoY Change 699.16% 103.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.49M $16.64M $16.64M
Total Long-Term Liabilities $7.640M $2.176M $2.176M
Total Liabilities $20.13M $18.81M $18.81M
YoY Change 100.36% -37.99% -37.99%
SHAREHOLDERS EQUITY
Retained Earnings -$146.0M -$122.0M
YoY Change 153.83%
Common Stock $474.0M $471.6M
YoY Change 116337.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $325.9M $347.5M $347.5M
YoY Change
Total Liabilities & Shareholders Equity $346.0M $366.3M $366.3M
YoY Change 91.58% 641.89% 641.89%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$23.93M -$23.44M -$73.96M
YoY Change 94.95% 19.25% 106.13%
Depreciation, Depletion And Amortization $800.0K $809.0K $2.100M
YoY Change 166.67% 262.78% 320.0%
Cash From Operating Activities -$27.40M -$14.17M -$59.36M
YoY Change 98.36% 65.29% 157.51%
INVESTING ACTIVITIES
Capital Expenditures $1.687M -$3.059M $9.732M
YoY Change -23.91% 157.93% 187.16%
Acquisitions
YoY Change
Other Investing Activities -$178.8M $12.00K $79.00K
YoY Change
Cash From Investing Activities -$180.5M -$3.047M -$9.653M
YoY Change 8042.53% 156.91% 184.83%
FINANCING ACTIVITIES
Cash Dividend Paid $0.00 $0.00
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 153.0K -135.0K 377.6M
YoY Change -99.89% 1250.0% 528.64%
NET CHANGE
Cash From Operating Activities -27.40M -14.17M -59.36M
Cash From Investing Activities -180.5M -3.047M -9.653M
Cash From Financing Activities 153.0K -135.0K 377.6M
Net Change In Cash -207.8M -17.35M 308.5M
YoY Change -263.94% 77.63% 817.8%
FREE CASH FLOW
Cash From Operating Activities -$27.40M -$14.17M -$59.36M
Capital Expenditures $1.687M -$3.059M $9.732M
Free Cash Flow -$29.09M -$11.11M -$69.10M
YoY Change 81.46% 50.42% 161.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2020 glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
CY2021Q4 glue Preferred Stock Tranche Obligations Current
PreferredStockTrancheObligationsCurrent
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2020 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001826457
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
CY2020 glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 glue Conversion Of Convertible Note Payable And Accrued Interest Into Series A Convertible Preferred Stock
ConversionOfConvertibleNotePayableAndAccruedInterestIntoSeriesAConvertiblePreferredStock
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Entity File Number
EntityFileNumber
001-40522
CY2021 dei Entity Registrant Name
EntityRegistrantName
Monte Rosa Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3766197
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
645 Summer Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Local Phone Number
LocalPhoneNumber
949-2643
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
GLUE
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02210
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
654700000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46630325
CY2021 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
346071000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41699000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2595000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1892000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
348666000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
43591000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4623000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5338000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1164000
CY2021Q4 us-gaap Assets
Assets
366329000
CY2020Q4 us-gaap Assets
Assets
49378000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6558000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7066000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10080000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2529000
CY2020Q4 glue Preferred Stock Tranche Obligations Current
PreferredStockTrancheObligationsCurrent
19680000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16638000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29275000
CY2021Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
2176000
CY2020Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
1067000
CY2021Q4 us-gaap Liabilities
Liabilities
18814000
CY2020Q4 us-gaap Liabilities
Liabilities
30342000
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
77631514
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
53631514
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
53631514
CY2021Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
0
CY2020Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
67764000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46794295
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46535966
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
97500000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2180803
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1685534
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
471566000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
404000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2021000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1056000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122035000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48077000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
347515000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
48728000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
366329000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49378000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57155000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24005000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15727000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4005000
CY2021 us-gaap Operating Expenses
OperatingExpenses
72882000
CY2020 us-gaap Operating Expenses
OperatingExpenses
28010000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-72882000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-28010000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
46000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-162000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-198000
CY2021 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-73958000
CY2020 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-7680000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1076000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35879000
CY2021 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-965000
CY2020 glue Provision For Pension Benefit Obligation
ProvisionForPensionBenefitObligation
-1056000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74923000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36935000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7869000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-73958000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35879000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.96
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.65
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25000124
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1516912
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
12148000
CY2020 glue Stock Issued During Period Value Restricted Stock Award Vesting
StockIssuedDuringPeriodValueRestrictedStockAwardVesting
1000
CY2020 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1056000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
354000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35879000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
48728000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
231173000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
234645000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5200000
CY2021 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-965000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-73958000
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
347515000
CY2021 us-gaap Profit Loss
ProfitLoss
-73958000
CY2020 us-gaap Profit Loss
ProfitLoss
-35879000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5200000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
354000
CY2021 us-gaap Depreciation
Depreciation
2132000
CY2020 us-gaap Depreciation
Depreciation
537000
CY2021 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-960000
CY2020 glue Changes In Fair Value Of Preferred Stock Tranche Obligations Net
ChangesInFairValueOfPreferredStockTrancheObligationsNet
-7680000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-17000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
704000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1377000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-706000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3435000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6587000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1130000
CY2021 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-1109000
CY2020 us-gaap Defined Benefit Plan Other Changes
DefinedBenefitPlanOtherChanges
-1067000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59363000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23053000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9732000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3389000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
79000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9653000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3389000
CY2021 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
143000000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
60500000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
231000
CY2021 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
3106000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
149000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
440000
CY2021 glue Proceed From Initial Public Offering Net Of Underwriting Discount
ProceedFromInitialPublicOfferingNetOfUnderwritingDiscount
17895000
CY2020 glue Proceed From Initial Public Offering Net Of Underwriting Discount
ProceedFromInitialPublicOfferingNetOfUnderwritingDiscount
17895000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
237750000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
377562000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60060000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
308546000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33618000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9245000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
346071000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41699000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
5338000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1164000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351409000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42863000
CY2021 glue Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
231172000
CY2021 glue Settlement Of Preferred Stock Tranche Obligation
SettlementOfPreferredStockTrancheObligation
20640000
CY2020 glue Conversion Of Convertible Note Payable And Accrued Interest Into Series A Convertible Preferred Stock
ConversionOfConvertibleNotePayableAndAccruedInterestIntoSeriesAConvertiblePreferredStock
754000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
656000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
458000
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-3.5305
CY2021Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
31068102
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122000000.0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-74000000.0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35900000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
351400000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">preparation of the combined and consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an ongoing basis, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">evaluates its estimates, including those related to accrued research and development expenses, other long-lived assets, pension benefit obligation, stock- based compensation and the valuation of deferred tax assets. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1100000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000000.0
CY2021 glue Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
8000000.0
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000000.0
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
320800000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
39929000
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
19680000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15028000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5232000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2703000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
609000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12325000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4623000
CY2021 us-gaap Depreciation
Depreciation
2100000
CY2020 us-gaap Depreciation
Depreciation
500000
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
100000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
90381
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.63
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
478811
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.62
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5563513
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.92
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4303000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1129000
CY2021Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
4937000
CY2020Q4 glue Accrued Research And Development
AccruedResearchAndDevelopment
0
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
840000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1400000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10080000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2529000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2300000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3160000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
8353000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8583000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
8820000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
7298000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
44784000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
80998000
CY2021Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
31068102
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46794295
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46535966
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021 us-gaap Payments Of Dividends
PaymentsOfDividends
0
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5821842
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
56332172
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2205380
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.05
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
312000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3927325
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.43
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70045000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7775
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7590
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0053
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
58000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
538889
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.76
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8979000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
5200000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.13
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.88
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5200000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
354000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25100000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
200000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y18D
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9884000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10107000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-64074000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-25772000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-73958000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35879000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.012
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.069
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.057
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.045
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.016
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.197
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.178
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14529000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5810000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1862000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
413000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
1738000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
52000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18187000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6275000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17777000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6040000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
410000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
235000
CY2021Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
125000
CY2020Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
137000
CY2021Q4 glue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
285000
CY2020Q4 glue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
98000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
410000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
235000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
23800000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
2284000
CY2019Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
0
CY2021 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
417000
CY2020 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
63000
CY2021 glue Defined Benefit Plan Contributions Paid By Employees
DefinedBenefitPlanContributionsPaidByEmployees
170000
CY2020 glue Defined Benefit Plan Contributions Paid By Employees
DefinedBenefitPlanContributionsPaidByEmployees
26000
CY2021 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
9000
CY2020 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
0
CY2021 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
1926000
CY2020 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
1154000
CY2021 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
82000
CY2020 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
15000
CY2021 us-gaap Defined Benefit Plan Plan Amendments
DefinedBenefitPlanPlanAmendments
-42000
CY2020 us-gaap Defined Benefit Plan Plan Amendments
DefinedBenefitPlanPlanAmendments
0
CY2021 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
1293000
CY2020 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
1056000
CY2021Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
5975000
CY2020Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
2284000
CY2020Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
1217000
CY2019Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
0
CY2021 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
226000
CY2020 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
1000
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
340000
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
51000
CY2021 glue Defined Benefit Plan Assets Contributions Paid By Employees
DefinedBenefitPlanAssetsContributionsPaidByEmployees
175000
CY2020 glue Defined Benefit Plan Assets Contributions Paid By Employees
DefinedBenefitPlanAssetsContributionsPaidByEmployees
26000
CY2021 us-gaap Defined Benefit Plan Plan Assets Contributions By Plan Participant
DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
1926000
CY2020 us-gaap Defined Benefit Plan Plan Assets Contributions By Plan Participant
DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
1154000
CY2021 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
85000
CY2020 us-gaap Defined Benefit Plan Plan Assets Benefits Paid
DefinedBenefitPlanPlanAssetsBenefitsPaid
15000
CY2021Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
3799000
CY2020Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
1217000
CY2021Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
2176000
CY2020Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
1067000
CY2021 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
417000
CY2020 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
63000
CY2021 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
417000
CY2020 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
63000
CY2021 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
1293000
CY2020 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
1056000
CY2021 us-gaap Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax
AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
1293000
CY2020 us-gaap Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax
AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
1056000
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate
0.0050
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Inflation Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInflationRate
0.0050
CY2021 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.0035
CY2020 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.0020
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Interest Rate On Savings Accounts
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestRateOnSavingsAccounts
0.0045
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Interest Rate On Savings Accounts
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestRateOnSavingsAccounts
0.0045
CY2021 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.0045
CY2020 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.0045
CY2021 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0100
CY2020 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0.0100
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Social Security Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostSocialSecurityIncrease
0.0050
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Social Security Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostSocialSecurityIncrease
0.0050
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Pension Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPensionIncrease
0.0000
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Pension Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostPensionIncrease
0.0000
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Retirement Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRetirementDescription
100% Male 65 Female 64
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Retirement Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRetirementDescription
100% Male 65 Female 64
CY2021 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Mortality And Disability Rate Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostMortalityAndDisabilityRateDescription
BVG 2020 Table
CY2020 glue Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Mortality And Disability Rate Description
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostMortalityAndDisabilityRateDescription
BVG 2015 Table
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months
DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
418000
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Two
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
434000
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Three
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
445000
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Four
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
452000
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Five
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
458000
CY2021Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter
DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
2360000
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-73958000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-35879000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.96
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.65
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25000124
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1516912

Files In Submission

Name View Source Status
0000950170-22-004927-index-headers.html Edgar Link pending
0000950170-22-004927-index.html Edgar Link pending
0000950170-22-004927.txt Edgar Link pending
0000950170-22-004927-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glue-20211231.htm Edgar Link pending
glue-20211231.xsd Edgar Link pending
glue-20211231_cal.xml Edgar Link unprocessable
glue-20211231_def.xml Edgar Link unprocessable
glue-20211231_htm.xml Edgar Link completed
glue-20211231_lab.xml Edgar Link unprocessable
glue-20211231_pre.xml Edgar Link unprocessable
glue-ex10_20.htm Edgar Link pending
glue-ex10_21.htm Edgar Link pending
glue-ex10_22.htm Edgar Link pending
glue-ex21_1.htm Edgar Link pending
glue-ex23_1.htm Edgar Link pending
glue-ex31_1.htm Edgar Link pending
glue-ex31_2.htm Edgar Link pending
glue-ex32_1.htm Edgar Link pending
glue-ex4_2.htm Edgar Link pending
img7466836_0.jpg Edgar Link pending
img7466836_1.jpg Edgar Link pending
img7466836_10.jpg Edgar Link pending
img7466836_11.jpg Edgar Link pending
img7466836_12.jpg Edgar Link pending
img7466836_13.jpg Edgar Link pending
img7466836_14.jpg Edgar Link pending
img7466836_15.jpg Edgar Link pending
img7466836_16.jpg Edgar Link pending
img7466836_17.jpg Edgar Link pending
img7466836_18.jpg Edgar Link pending
img7466836_19.jpg Edgar Link pending
img7466836_2.jpg Edgar Link pending
img7466836_20.jpg Edgar Link pending
img7466836_21.jpg Edgar Link pending
img7466836_22.jpg Edgar Link pending
img7466836_23.jpg Edgar Link pending
img7466836_24.jpg Edgar Link pending
img7466836_25.jpg Edgar Link pending
img7466836_26.jpg Edgar Link pending
img7466836_27.jpg Edgar Link pending
img7466836_28.jpg Edgar Link pending
img7466836_29.jpg Edgar Link pending
img7466836_3.jpg Edgar Link pending
img7466836_4.jpg Edgar Link pending
img7466836_5.jpg Edgar Link pending
img7466836_6.jpg Edgar Link pending
img7466836_7.jpg Edgar Link pending
img7466836_8.jpg Edgar Link pending
img7466836_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending